Second quarter 2014 net income of $7.5 million, or $.22 per diluted share Solid organic loan growth and lower noninterest expenses Signed two definitive merger agreements ATLANTA, July 24, 2014 (GLOBE NEWSWIRE) -- State Bank Financial Corporation (Nasdaq:STBZ) today announced unaudited financial results for the quarter ended June 30, 2014.
NeoPhotonics Corporation (NYSE: NPTN), a leading designer and
manufacturer of photonic integrated circuits, or PIC, based
optoelectronic modules and subsystems for bandwidth-intensive, high
speed communications networks, today announced financial results for its
second quarter ended June 30, 2014.
Norsat Announces 2014 Second Quarter Financial Results Canada NewsWire
Norsat's Revenues up 11% to $9.6 million and posts Adjusted EBITDA of $1.3 million - Management to Host Conference Call at 8:30 am Pacific Time ( 11:30 am Eastern Time ) - VANCOUVER , Aug.
Qlik (NASDAQ: QLIK), a leader in data discovery delivering intuitive
solutions for self-service data visualization and guided analytics,
today announced financial results for the second quarter ended June 30,
Expansion of investment management offering with the acquisition of Cherry Hills Investment Advisors Net income increased 15.3% in the second quarter 2014 as compared to the first quarter 2014 Net loans grew 22.3% on an annualized basis during the second quarter 2014 Net commercial loans grew 26.1% on an annualized basis during the second quarter 2014
DENVER, July 23, 2014 (GLOBE NEWSWIRE) -- Guaranty Bancorp (Nasdaq:GBNK) ("we", "our" or "the Company"), a community bank holding company based in Colorado, today announced second quarter 2014 net income of $4.1 million or $0.19 per basic and diluted common share, an increase of $0.3 million or $0.01 per basic and diluted common share as compared to the same quarter in 2013.
Open Bank (OTCBB:OPBK) today reported that income before taxes increased
15.8% to $2.0 million for the three months ended June 30, 2014, up from
$1.8 million for the three months ended March 31, 2014 and up 117.3%
from $933 thousand for the three months ended June 30, 2013.
– EC1456 Targeting Potent Tubulysin Payload to Advance in Phase 1 to Dose Similar to Vintafolide –
WEST LAFAYETTE, Ind., July 29, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) , a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the second quarter ending June 30, 2014, and provided a clinical update.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.